Related studies have shown that the expression of CYP3A4 is negatively correlated with the sensitivity of breast cancer patients to paclitaxel drugs in neoadjuvant chemotherapy, which may be related to changes in bioavailability caused by the interaction of CYP3A and P-gp [12]. This evidence concerns the gene PGP and breast carcinoma.